Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in...
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events.
JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.
Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases.
CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- XtalPi...
Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases.
CAMBRIDGE, Mass., Aug. 6, 2025 /PRNewswire/ -- XtalPi...
QUO Beauty®'s first-ever brand collaboration includes cosmetics, nail, and hair accessories inspired by Barbie™
TORONTO, Aug. 6, 2025 /CNW/ - Today, Mattel, Inc. (NASDAQ: MAT)...
Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune cells into attacking the malignant cells
Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune cells into attacking the malignant cells
SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...
Second Quarter 2025 Total Revenues of $825 million (+16% Y/Y and +17% at Constant Currency Y/Y)
Second Quarter 2025 GAAP Diluted Earnings Per Share (EPS)...
As consumer demand for clean beauty and functional supplements rises in 2025, marine collagen gummies like Pilly Labs are emerging as a preferred daily solution for supporting skin texture, joint mobility, and hair strength — all without powders, pills, or synthetic additives.
As consumer demand for clean beauty and functional supplements rises in 2025, marine collagen gummies like Pilly Labs are emerging as a preferred daily solution for supporting skin texture, joint mobility, and hair strength — all without powders, pills, or synthetic additives.